A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer-Reference-Cited by-同舟云学术

A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer

Published:2019-09-10 Issue:4 Volume:38 Page:1077-1084
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Goodwin Rachel,Jonker Derek,Chen Eric,Kennecke Hagen,Cabanero Michael,Tsao Ming-Sound,Vickers Michael,Bohemier Caryn,Lim Howard,Ritter Heather,Tu Dongsheng,Seymour Lesley

Funder

Canadian Cancer Society Research Institute

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-019-00814-3.pdf

Reference26 articles.

1. Canadian Cancer Statistics, Canadian Cancer Society's Advisory Committee on Cancer Statistics (2016)

2. Malvezzi M et al (2013) European cancer mortality predictions for the year 2013. Ann Oncol 24(3):792–800

3. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352(5):476–487

4. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7(10):2958–2970

5. Salomon DS et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19(3):183–232

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling pathways in colorectal cancer: implications for the target therapies;Molecular Biomedicine;2024-06-07

2. Targeted Treatment against Cancer Stem Cells in Colorectal Cancer;International Journal of Molecular Sciences;2024-06-05

3. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment;International Journal of Molecular Sciences;2024-03-09

4. Colorectal Cancer Stem Cells and Targeted Agents;Pharmaceutics;2023-12-12

5. Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer;Cancer Biology & Therapy;2023-06-16